Fertility and Sterility
Volume 94, Issue 3 , Pages 958-964 , August 2010

A prospective, randomized, controlled trial comparing three different gonadotropin regimens in oocyte donors: ovarian response, in vitro fertilization outcome, and analysis of cost minimization

  • Marco Melo, M.D.

      Affiliations

    • Instituto Valenciano de Infertilidad, Universidad de Valencia, Valencia, Spain
    • Corresponding Author InformationReprint requests: Marco Melo, M.D., Instituto Valenciano de Infertilidad, Plaza de la Policía Local, 3, Valencia, 46015, Spain (FAX: 34-96-3050999).
    • ,
  • José Bellver, M.D.

      Affiliations

    • Instituto Valenciano de Infertilidad, Universidad de Valencia, Valencia, Spain
    • ,
  • Nicolás Garrido, Ph.D.

      Affiliations

    • Instituto Valenciano de Infertilidad, Universidad de Valencia, Valencia, Spain
    • Fundación IVI, University Hospital Dr. Peset, Valencia, Spain
    • ,
  • Marcos Meseguer, Ph.D.

      Affiliations

    • Instituto Valenciano de Infertilidad, Universidad de Valencia, Valencia, Spain
    • Fundación IVI, University Hospital Dr. Peset, Valencia, Spain
    • ,
  • Antonio Pellicer, M.D.

      Affiliations

    • Instituto Valenciano de Infertilidad, Universidad de Valencia, Valencia, Spain
    • Fundación IVI, University Hospital Dr. Peset, Valencia, Spain
    • Department of Obstetrics and Gynaecology, University Hospital Dr. Peset, Valencia, Spain
    • ,
  • José Remohí, M.D.

      Affiliations

    • Instituto Valenciano de Infertilidad, Universidad de Valencia, Valencia, Spain

Received 26 March 2009 ,Revised 25 April 2009 ,Accepted 4 May 2009.

References 

  1. Daya S, Gunby J, Hughes EG, Collins JA, Sagle MA. Follicle-stimulating hormone versus human menopausal gonadotropin for in vitro fertilization cycles: a meta-analysis. Fertil Steril. 1995;64:347–354
  2. Daya S. Follicle-stimulating hormone and human menopausal gonadotropin for ovarian stimulation in assisted reproduction cycles. Cochrane Database Syst Rev. 1996;22(1):CD000061
  3. Agrawal R, Holmes J, Jacobs HS. Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis. Fertil Steril. 2000;73:338–343
  4. Daya S. Follicle-stimulating hormone and human menopausal gonadotropin for ovarian stimulation in assisted reproduction cycles. Cochrane Database Syst Rev. 2000;(2):CD000061
  5. Al-Inany H, Aboulghar M, Mansour R, Serour G. Meta-analysis of recombinant versus urinary-derived FSH: an update. Hum Reprod. 2003;18:305–313
  6. van Wely M, Westergaard LG, Bossuyt PM, Van der Veen F. Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database Syst Rev. 2003;(1):CD003973
  7. van Wely M, Westergaard LG, Bossuyt PM, van der Veen F. Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis. Fertil Steril. 2003;80:1086–1093
  8. Ziebe S, Lundin K, Janssens R, Helmgaard L, Arce JC MERIT (Menotrophin vs Recombinant FSH in vitro Fertilisation Trial) Group. Influence of ovarian stimulation with HP-hMG or recombinant FSH on embryo quality parameters in patients undergoing IVF. Hum Reprod. 2007;22:2404–2413
  9. Smitz J, Andersen AN, Devroey P, Arce JC MERIT Group. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients. Hum Reprod. 2007;22:676–687
  10. Al-Inany HG, Abou-Setta AM, Aboulghar MA, Mansour RT, Serour GI. Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis. Reprod Biomed Online. 2008;16:81–88
  11. Coomarasamy A, Afnan M, Cheema D, van der Veen F, Bossuyt PM, van Wely M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod. 2008;23:310–315
  12. Platteau P, Nyboe Andersen A, Loft A, Smitz J, Danglas P, Devroey P. Highly purified HMG versus recombinant FSH for ovarian stimulation in IVF cycles. Reprod Biomed Online. 2008;17:190–198
  13. Melo MAB, Meseguer M, Garrido N, Bosch E, Pellicer A, Remohi J. The significance of premature luteinization in an oocyte-donation programme. Hum Reprod. 2006;21:1503–1507
  14. Garrido N, Zuzuarregui JL, Meseguer M, Simon C, Remohi J, Pellicer A. Sperm and oocyte selection and management: experience of a 10 year follow-up of more than 2100 candidates. Hum Reprod. 2002;17:3142–3147
  15. Melo MAB, Garrido N, Alvarez C, Bellver J, Meseguer M, Pellicer A, et al. Antral follicle count (AFC) can be used in the prediction of ovarian response but cannot predict the oocyte/embryo quality or the in vitro fertilization outcome in an egg donation program. Fertil Steril. 2009;91:148–156
  16. Golan A, Ron-El R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989;44:430–440
  17. Remohí J, Gutiérrez A, Cano F, Ruiz A, Simon C, Pellicer A. Long oestradiol replacement in an oocyte donation programme. Hum Reprod. 1995;10:1387–1391
  18. Alikani M, Calderón G, Tomkin G, Garrisi J, Kokos M, Cohen J. Cleavage anomalies in early human embryos and survival after prolonged culture in vitro. Hum Reprod. 2000;15:2634–2643
  19. Kilani Z, Dakkak A, Ghunaim S, Cognigni GE, Tabarelli C, Parmegiani LM, et al. A prospective, randomized, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes. Hum Reprod. 2003;18:1194–1199
  20. Andersen AN, Devroey P, Arce JC. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor–blind controlled trial. Hum Reprod. 2006;21:3217–3227
  21. Hompes PG, Broekmans FJ, Hoozemans DA, Schats R FIRM group. Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization–intracytoplasmic sperm injection patients. Fertil Steril. 2008;89:1685–1693
  22. Revelli A, Poso F, Gennarelli G, Moffa F, Grassi G, Massobrio M. Recombinant versus highly-purified, urinary follicle-stimulating hormone (r-FSH vs. HP-uFSH) in ovulation induction: a prospective, randomized study with cost-minimization analysis. Reprod Biol Endocrinol. 2006;4:38
  23. Lloyd A, Kennedy R, Hutchinson J, Sawyer W. Economic evaluation of highly purified menotropin compared with recombinant follicle-stimulating hormone in assisted reproduction. Fertil Steril. 2003;80:1108–1113
  24. Weghofer A, Munné S, Brannath W, Chen S, Tomkin G, Cekleniak N, et al. The impact of LH-containing gonadotropins on diploidy rates in preimplantation embryos: long protocol stimulation. Hum Reprod. 2008;23:499–503
  25. Sullivan MW, Stewart-Akers A, Krasnow JS, Berga SL, Zeleznik AJ. Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation. J Clin Endocrinol Metab. 1999;84:228–232
  26. Filicori M, Cognigni GE, Taraborrelli S, Spettoli D, Ciampaglia W, Tabarelli De Fatis C, et al. Luteinizing hormone activity in menotropins optimizes folliculogenesis and treatment in controlled ovarian stimulation. J Clin Endocrinol Metab. 2001;86:337–343
  27. Filicori M, Cognigni GE, Pocognoli P, Tabarelli C, Spettoli D, Taraborrelli S, et al. Modulation of folliculogenesis and steroidogenesis in women by graded menotrophin administration. Hum Reprod. 2002;17:2009–2015
  28. Filicori M, Cognigni GE, Samara A, Melappioni S, Perri T, Cantelli B, et al. The use of LH activity to drive folliculogenesis: exploring uncharted territories in ovulation induction. Hum Reprod Update. 2002;8:543–557
  29. Loumaye E, Engrand P, Shoham Z, Hillier SG, Baird DT. Clinical evidence for an LH ceiling' effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation. Hum Reprod. 2003;18:314–322
  30. Platteau P, Smitz J, Albano C, Sørensen P, Arce JC, Devroey P. Exogenous luteinizing hormone activity may influence the treatment outcome in in vitro fertilization but not in intracytoplasmic sperm injection cycles. Fertil Steril. 2004;81:1401–1404
  31. Lisi F, Rinaldi L, Fishel S, Caserta D, Lisi R, Campbell A. Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertil Steril. 2005;83:309–315
  32. Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod. 2000;15:1003–1008
  33. Agrawal R, Conway GS, Engmann L, Bekir JS, Jacobs HS. Implications of using follicle-stimulating hormone preparations depleted of luteinizing hormone to achieve follicular growth in in vitro fertilization. Gynecol Endocrinol. 1998;12:9–15
  34. Weston AM, Zelinski-Wooten MB, Hutchison JS, Stouffer RL, Wolf DP. Developmental potential of embryos produced by in-vitro fertilization from gonadotrophin-releasing hormone antagonist-treated macaques stimulated with recombinant human follicle stimulating hormone alone or in combination with luteinizing hormone. Hum Reprod. 1996;11:608–613
  35. European and Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating Hormone. Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial. Fertil Steril. 2002;78:520–528
  36. Filicori M, Fazleabas AT, Huhtaniemi I, Licht P, ChV Rao, Tesarik J, et al. Novel concepts of human chorionic gonadotropin: reproductive system interactions and potential in the management of infertility. Fertil Steril. 2005;84:275–284
  37. Wechowski J, Connolly M, McEwan P, Kennedy R. An economic evaluation of highly purified HMG and recombinant FSH based on a large randomized trial. Reprod Biomed Online. 2007;15:500–506

 M.M. has nothing to disclose. J.B. has nothing to disclose. N.G. has nothing to disclose. M.M. has nothing to disclose. A.P. has nothing to disclose. J.R. has nothing to disclose.

PII: S0015-0282(09)01080-2

doi: 10.1016/j.fertnstert.2009.05.005

Fertility and Sterility
Volume 94, Issue 3 , Pages 958-964 , August 2010

Article Tools